How Is the Spectrum of Sarcoma Surgery Assessed?
Purpose: To meet the challenges of the precision medicine era, quality assessment of shared sarcoma care becomes pivotal. The MDT approach is the most important parameter for a successful outcome. Of all MDT disciplines, surgery is the key step to rendering sarcoma patients disease free; therefore,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/4/1305 |
| _version_ | 1797621888599457792 |
|---|---|
| author | Carlo Theus-Steinmann Georg Schelling Philip Heesen Stefan Breitenstein Mario F. Scaglioni Bruno Fuchs |
| author_facet | Carlo Theus-Steinmann Georg Schelling Philip Heesen Stefan Breitenstein Mario F. Scaglioni Bruno Fuchs |
| author_sort | Carlo Theus-Steinmann |
| collection | DOAJ |
| description | Purpose: To meet the challenges of the precision medicine era, quality assessment of shared sarcoma care becomes pivotal. The MDT approach is the most important parameter for a successful outcome. Of all MDT disciplines, surgery is the key step to rendering sarcoma patients disease free; therefore, defining its spectrum is critical. To the best of the authors’ knowledge, a comprehensive interoperable digital platform to assess the scope of sarcoma surgery in its full complexity is lacking. Methods: An interoperable digital platform on sarcoma surgery has been created to assess the clinical exposure, tumor characteristics, and surgical settings and techniques applied for both resections and reconstructions of sarcomas. Results: The surgical exposure of an individual surgeon over time served as a pilot. Over the study period of 10 years, there were 723 sarcoma board/MDT meetings discussing 3130 patients. A total of 1094 patients underwent 1250 surgical interventions on mesenchymal tumors by one single sarcoma surgeon. These included 615 deep soft tissue tumors (197 benign, 102 intermediate, 281 malignant, 27 simulator, 7 metastasis, 1 blood); 116 superficial soft tissue tumors (45 benign, 12 intermediate, 40 malignant, 18 simulator, 1 blood); and 519 bone tumors (129 benign, 112 intermediate, 182 malignant, 18 simulator, 46 metastasis, 14 blood, and 18 sequelae of first treatment). Detailed types of resections and reconstructions were analyzed. Conclusions: An interoperable digital data platform on sarcoma surgery with transparent real-time descriptive analytics is feasible and enables large-scale definition of the spectrum of sarcoma surgery to meet the challenges of sarcoma precision care in the future. |
| first_indexed | 2024-03-11T09:02:20Z |
| format | Article |
| id | doaj.art-ced18f1bb6c342b6975ec3cc76e072c4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:02:20Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ced18f1bb6c342b6975ec3cc76e072c42023-11-16T19:39:08ZengMDPI AGCancers2072-66942023-02-01154130510.3390/cancers15041305How Is the Spectrum of Sarcoma Surgery Assessed?Carlo Theus-Steinmann0Georg Schelling1Philip Heesen2Stefan Breitenstein3Mario F. Scaglioni4Bruno Fuchs5Swiss Sarcoma Network (SSN), Luzerner Kantonsspital (LUKS), Kantonsspital Winterthur (KSW), 6000 Luzern, SwitzerlandSwiss Sarcoma Network (SSN), Luzerner Kantonsspital (LUKS), Kantonsspital Winterthur (KSW), 6000 Luzern, SwitzerlandSwiss Sarcoma Network (SSN), Luzerner Kantonsspital (LUKS), Kantonsspital Winterthur (KSW), 6000 Luzern, SwitzerlandSwiss Sarcoma Network (SSN), Luzerner Kantonsspital (LUKS), Kantonsspital Winterthur (KSW), 6000 Luzern, SwitzerlandSwiss Sarcoma Network (SSN), Luzerner Kantonsspital (LUKS), Kantonsspital Winterthur (KSW), 6000 Luzern, SwitzerlandSwiss Sarcoma Network (SSN), Luzerner Kantonsspital (LUKS), Kantonsspital Winterthur (KSW), 6000 Luzern, SwitzerlandPurpose: To meet the challenges of the precision medicine era, quality assessment of shared sarcoma care becomes pivotal. The MDT approach is the most important parameter for a successful outcome. Of all MDT disciplines, surgery is the key step to rendering sarcoma patients disease free; therefore, defining its spectrum is critical. To the best of the authors’ knowledge, a comprehensive interoperable digital platform to assess the scope of sarcoma surgery in its full complexity is lacking. Methods: An interoperable digital platform on sarcoma surgery has been created to assess the clinical exposure, tumor characteristics, and surgical settings and techniques applied for both resections and reconstructions of sarcomas. Results: The surgical exposure of an individual surgeon over time served as a pilot. Over the study period of 10 years, there were 723 sarcoma board/MDT meetings discussing 3130 patients. A total of 1094 patients underwent 1250 surgical interventions on mesenchymal tumors by one single sarcoma surgeon. These included 615 deep soft tissue tumors (197 benign, 102 intermediate, 281 malignant, 27 simulator, 7 metastasis, 1 blood); 116 superficial soft tissue tumors (45 benign, 12 intermediate, 40 malignant, 18 simulator, 1 blood); and 519 bone tumors (129 benign, 112 intermediate, 182 malignant, 18 simulator, 46 metastasis, 14 blood, and 18 sequelae of first treatment). Detailed types of resections and reconstructions were analyzed. Conclusions: An interoperable digital data platform on sarcoma surgery with transparent real-time descriptive analytics is feasible and enables large-scale definition of the spectrum of sarcoma surgery to meet the challenges of sarcoma precision care in the future.https://www.mdpi.com/2072-6694/15/4/1305sarcomamultidisciplinary team/MDTsarcoma surgeryorthopedic oncologyreal-world datainteroperable digital platform |
| spellingShingle | Carlo Theus-Steinmann Georg Schelling Philip Heesen Stefan Breitenstein Mario F. Scaglioni Bruno Fuchs How Is the Spectrum of Sarcoma Surgery Assessed? Cancers sarcoma multidisciplinary team/MDT sarcoma surgery orthopedic oncology real-world data interoperable digital platform |
| title | How Is the Spectrum of Sarcoma Surgery Assessed? |
| title_full | How Is the Spectrum of Sarcoma Surgery Assessed? |
| title_fullStr | How Is the Spectrum of Sarcoma Surgery Assessed? |
| title_full_unstemmed | How Is the Spectrum of Sarcoma Surgery Assessed? |
| title_short | How Is the Spectrum of Sarcoma Surgery Assessed? |
| title_sort | how is the spectrum of sarcoma surgery assessed |
| topic | sarcoma multidisciplinary team/MDT sarcoma surgery orthopedic oncology real-world data interoperable digital platform |
| url | https://www.mdpi.com/2072-6694/15/4/1305 |
| work_keys_str_mv | AT carlotheussteinmann howisthespectrumofsarcomasurgeryassessed AT georgschelling howisthespectrumofsarcomasurgeryassessed AT philipheesen howisthespectrumofsarcomasurgeryassessed AT stefanbreitenstein howisthespectrumofsarcomasurgeryassessed AT mariofscaglioni howisthespectrumofsarcomasurgeryassessed AT brunofuchs howisthespectrumofsarcomasurgeryassessed |